Jounce Therapeutics to Present at Upcoming Investor Conferences in March
Last jounce therapeutics, inc earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at several upcoming investor conferences: Cowen & Co. 41st Annual Health Care Conference: A panel discussion will be available live to conference attendees on Monday, March 1, 2021 at 10:30 a.m. ET.42nd Annual Raymond James Institutional Investors Conference: A live webcast fireside chat will take place on Tuesday, March 2, 2021 at 3:50 p.m. ET.H.C. Wainwright Global Life Sciences Conference: A webcast presentation will be available on demand during the conference, starting Tuesday, March 9, 2021 at 7:00 a.m. ET.33rd Annual ROTH Conference: A live webcast panel discussion will take place on Monday, March 15, 2021 at 2:00 p.m. ET. Presentation webcasts will be available by visiting “Events and Presentations” in the
[Read more]
| Impact snapshot | Event time: | JNCE | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
JNCE alerts
JNCE alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNCE alerts
High impacting Jounce Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
JNCE
News
- Jounce Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/">NASDAQ: JNCE</a>) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.MarketBeat
- Jounce Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/">NASDAQ: JNCE</a>) had its "buy" rating re-affirmed by analysts at Robert W. Baird.MarketBeat
- Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2020 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call Transcript [The Motley Fool]The Motley Fool
- Jounce Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/">NASDAQ: JNCE</a>) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock, up previoMarketBeat
- More
JNCE
SEC Filings
- 3/3/21 - Form 4
- 3/3/21 - Form 4
- 2/25/21 - Form S-8
- JNCE's page on the SEC website
- More